Patient pretreatment characteristics
| Pretreatment characteristic . | Mean . | Median . | Range . |
|---|---|---|---|
| Age, y | 59.4 | 59.5 | 39-79 |
| Hemoglobin, g/dL | 11.8 | 11.4 | 8.2-16.9 |
| Platelets, × 109/L | 131 | 122 | 14-349 |
| ANC, × 109/L | 2.46 | 2.21 | 0-9.74 |
| Lymphocytes, × 109/L | 64.0 | 44.9 | 0.04-320 |
| β2-microglobulin, mg/L | 4.6 | 4.1 | 1.7-11.3 |
| LDH, IU/L* | 818 | 685 | 248-3883 |
| Albumin, g/dL | 4.0 | 4.1 | 1.9-5.0 |
| No. of prior treatments | 3.4 | 3 | 1-14 |
| Zap-70, flow (ND = 36, 45%) | < 20% | n = 14 | 18% of total |
| > 20% | n = 30 | 38% of total | |
| IGHV mutational status (ND = 34, 43%) | Mutated | n = 5 | 6% of total |
| Unmutated | n = 41 | 51% of total |
| Pretreatment characteristic . | Mean . | Median . | Range . |
|---|---|---|---|
| Age, y | 59.4 | 59.5 | 39-79 |
| Hemoglobin, g/dL | 11.8 | 11.4 | 8.2-16.9 |
| Platelets, × 109/L | 131 | 122 | 14-349 |
| ANC, × 109/L | 2.46 | 2.21 | 0-9.74 |
| Lymphocytes, × 109/L | 64.0 | 44.9 | 0.04-320 |
| β2-microglobulin, mg/L | 4.6 | 4.1 | 1.7-11.3 |
| LDH, IU/L* | 818 | 685 | 248-3883 |
| Albumin, g/dL | 4.0 | 4.1 | 1.9-5.0 |
| No. of prior treatments | 3.4 | 3 | 1-14 |
| Zap-70, flow (ND = 36, 45%) | < 20% | n = 14 | 18% of total |
| > 20% | n = 30 | 38% of total | |
| IGHV mutational status (ND = 34, 43%) | Mutated | n = 5 | 6% of total |
| Unmutated | n = 41 | 51% of total |
LDH indicates lactate dehydrogenase; and ND, not done.
LDH normal range: 313-618 IU/L.